John Tsai, Novartis R&D chief
October 7, 2021 08:47 AM EDT
R&D

Em­bold­ened by a pos­i­tive PhI­II, No­var­tis steers a late-stage BTK in­hibitor in­to a piv­otal MS tri­al

John Carroll

Editor & Founder

No­var­tis is tak­ing a dig­i­tal turn at the up­com­ing ECTRIMS con­fer­ence with dozens of ab­stracts on its im­munol­o­gy drugs al­ready on the mar­ket. And no­tably …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times